| 摘要 |
Novel pharmaceutical compositions comprising i) an hydrogenated ergot alkaloid having vaso-constrictor activity, for example dihydroergotamine, or a pharmaceutically acceptable acid addition salt thereof and ii) a low molecular weight heparin or pharmaceutically acceptable salt thereof, and process for their production. Components ii) suitably have an average molecular weight of less than 10,000. The compositions are especially useful in the prevention of post-operative thrombosis. |
